A few of us were chatting at the OHDSI Symposium about running a network study to characterize the inpatient sedation medication pathway for agitated patients. Putting the discussion on the forums so other people can join in.
I understand you’re trying to do a treatment pathway/characterization study. Just thought it would be helpful for the context in which you’re characterizing treatment. Could tell a much more powerful story if, for example, 90% of patients received antipsychotics as part of 1st-line therapy (which is generally what happens in practice, either that or Ativan, or both) and now we have recent evidence which says antipsychotics are not that helpful